Transdermal drug delivery and cutaneous metabolism

References

• Albery W. J., Guy R. H., Hadgraft J. Percutaneous absorption: transport in the dermis. International Journal of Pharmaceutics 1983; 15: 125–148
   Google Scholar
• Albery W. J., Hadgraft J. Percutaneous absorption: theoretical description. Journal of Pharmacy and Pharmacology 1979a; 31: 129–139
   PubMed Web of Science ®Google Scholar
• Albery W. J., Hadgraft J. Percutaneous absorption: in vivo experiments. Journal of Pharmacy and Pharmacology 1979b; 31: 140–147
   PubMed Web of Science ®Google Scholar
• Arndts D., Arndts K. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine. European Journal of Clinical Pharmacology 1984; 26: 79–85
   PubMed Web of Science ®Google Scholar
• Barry B. W. Dermatological Formulations: Percutaneous Absorption. Marcel Dekker, New York 1983
   Google Scholar
• Benet L. Z., Sheiner L. B. Design and Optimization of Dosage Regimens; Pharmacokinetic Data. The Pharmacological Basis of Therapeutics, 7th ed., A. G. Gilman, L. S. Goodman, T. W. Rall, F. Murad. Macmillan Publishing Co., New York 1985; 1663–1733
   Google Scholar
• Bucks D. A. W. Skin structure and metabolism: relevance to the design of cutaneous therapeutics. Pharmaceutical Research 1984; 1: 148–153
   PubMedGoogle Scholar
• Chandrasekaran S. K. Controlled release of scopolamine for prophylaxis of motion sickness. Drug Development and Industrial Pharmacy 1983; 9: 627–646
   Web of Science ®Google Scholar
• Chandrasekaran S. K., Bayne W., Shaw J. E. Pharmacokinetics of drug permeation through human skin. Journal of Pharmaceutical Sciences 1978; 67: 1370–1374
   PubMed Web of Science ®Google Scholar
• Denyer S. P., Guy R. H., Hadgraft J., Hugo W. B. The microbial degradation of topically applied drugs. International Journal of Pharmaceutics 1985; 26: 89–97
   Web of Science ®Google Scholar
• Denyer S. P., Hugo W. B., O'Brien M. Metabolism of glyceryl trinitrate by skin staphylococci. Journal of Pharmacy and Pharmacology 1984; 36: 61P
   PubMedGoogle Scholar
• Elias P. M. Epidermal lipids, barrier function, and desquamation. Journal of Investigative Dermatology 1983; 80: 44S–49S
   PubMedGoogle Scholar
• Fox J. L., Yu C. D., Higuchi W. I., Ho N. F. H. General physical model for simultaneous diffusion and metabolism in biological membranes. The computational approach for the steady-state case. International Journal of Pharmaceutics 1979; 2: 41–57
   Google Scholar
• Flynn G. L. Topical drug absorption and topical pharmaceutical systems. Modern Pharmaceutics, G. S. Banker, C. T. Rhodes. Marcel Dekker, New York 1979; 263–327
   Google Scholar
• Gienger G., Knock A., Merkle H. P. Modeling and numerical computation of drug transport in laminates: model case evaluation of transdermal delivery system. Journal of Pharmaceutical Sciences 1986; 75: 9–15
   PubMed Web of Science ®Google Scholar
• Good W. R. Transdermr`-Nitro controlled delivery of nitroglycerin via the transdermal route. Drug Development and Industrial Pharmacy 1983; 9: 647–670
   Web of Science ®Google Scholar
• Guy R. H., Hadgraft J. A theoretical description relating skin penetration to the thickness of the applied medicament. International Journal of Pharmaceutics 1980; 6: 321–332
   Web of Science ®Google Scholar
• Guy R. H., Hadgraft J. Percutaneous absorption with saturable metabolism. International Journal of Pharmaceutics 1982; 11: 187–197
   Web of Science ®Google Scholar
• Guy R. H., Hadgraft J. Physicochemical interpretation of the pharmacokinetics of percutaneous absorption. Journal of Pharmacokinetics and Biopharmaceutics 1983; 11: 189–203
   PubMedGoogle Scholar
• Guy R. H., Hadgraft J. Transdermal drug delivery: the ground rules are emerging. Pharmacy International 1985a; 6: 112–116
   Google Scholar
• Guy R. H., Hadgraft J. The prediction of plasma levels of drugs following transdermal application. Journal of Controlled Release 1985b; 1: 177–182
   Google Scholar
• Guy R. H., Hadgraft J. Kinetic analysis of transdermal nitroglycerin delivery. Pharmaceutical Research 1985c; 2: 206–211
   PubMedGoogle Scholar
• Guy R. H., Hadgraft J. Pharmacokinetic interpretation of the plasma levels of clonidine following transdermal delivery. Journal of Pharmaceutical Sciences 1985d; 74: 1016–1018
   PubMed Web of Science ®Google Scholar
• Guy R. H., Hadgraft J. Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine and timolol. International Journal of Pharmaceutics 1986; 32: 159–163
   Web of Science ®Google Scholar
• Guy R. H., Hadgraft J., Maibach H. I. Percutaneous absorption in man: a kinetic approach. Toxicology and Applied Pharmacology 1985; 78: 123–129
   PubMed Web of Science ®Google Scholar
• Hadgraft J. The epidermal reservoir: a theoretical approach. International Journal of Pharmaceutics 1979; 2: 177–194
   Web of Science ®Google Scholar
• Hadgraft J. Theoretical aspects of metabolism in the epidermis. International Journal of Pharmaceutics 1980; 4: 229–238
   Web of Science ®Google Scholar
• Heilmann K. Therapeutic Systems, 2nd ed. Thieme-Stratton, Inc., New York 1984; 37
   Google Scholar
• Imhof P. R., Vuillemin T., Gérardin A., Racine A., Müller P., Follath F. Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm-TTSr`). European Journal of Clinical Pharmacology 1984; 27: 7–12
   PubMedGoogle Scholar
• Kapp J. F., Koch H., Topert H., Kessler J., Gerhards E. Pharmacological studies on butyl 6a-fluoro-11β-hydroxy-16a-methyl-3,20-dioxo-1,4-pregnadien-21-oate (Fluocortin Butylester). Arzneimittel-Forschung 1977; 27: 2191–2202
   PubMedGoogle Scholar
• Karim A. Transdermal absorption: a unique opportunity for constant delivery of nitroglycerin. Drug Delivery and Industrial Pharmacy 1983a; 9: 671–689
   Web of Science ®Google Scholar
• Karim A. Transdermal absorption of nitroglycerin from a microsealed drug delivery (MMD) system. Angiology 1983b; 34: 11–21
   PubMed Web of Science ®Google Scholar
• Laufer L. R., Defazio J. L., Lu J. K. H., Meldrum D. R., Eggena P., Sambhi M. P., Hershman J. M., Judd H. L. Estrogen replacement therapy by transdermal estradiol administration. American Journal of Obstetrics and Gynecology 1983; 146: 533–540
   PubMed Web of Science ®Google Scholar
• Lawson A. A. H. Clinical and pharmacological studies with transdermal clonidine. Rate Control in Drug Therapy, L. F. Prescott, W. S. Nimmo. Churchill Livingstone, Edinburgh 1985; 215–219
   Google Scholar
• Michaels A. S., Chandrasekaran S. K., Shaw J. E. Drug permeation through human skin: theory and in vitro experimental measurement. American Institute of Chemical Engineering Journal 1975; 21: 985–996
   Web of Science ®Google Scholar
• Møllgaard B., Hoelgaard A., Bundgaard H. Pro-drugs as drug delivery systems XXII. Improved dermal delivery of 5-fluorouracil through human skin via N-acyloxymethyl pro-drug derivatives. International Journal of Pharmaceutics 1982; 12: 153–162
   Web of Science ®Google Scholar
• Montagna W. The Structure and Function of Skin, 3rd ed. Academic, New York 1974
   Google Scholar
• Muir C., Metcalfe R. A comparison of plasma levels of hyoscine after oral and transdermal administration. Journal of Pharmacological and Biomedical Analysis 1983; 1: 363–367
   PubMedGoogle Scholar
• Noonan P. K., Wester R. C. . Cutaneous metabolism of xenobiotics. Percutaneous Absorption, R. L. Bronaugh, H. I. Maibach. Marcel Dekker, New York 1985; 65–85
   Google Scholar
• Price N. M., Schmitt L. G., McGuire J., Shaw J. E., Trobough G. Transdermal scopolamine in the treatment of motion sickness at sea. Clinical Pharmacology and Therapeutics 1981; 29: 414–419
   PubMed Web of Science ®Google Scholar
• Rose J. E., Jarvik M. E., Rose K. D. Transdermal administration of nicotine. Drug and Alcohol Dependence 1985; 13: 209–213
   Google Scholar
• Schenkel L., Balestra J., Schmitt L., Shaw J. Transdermal oestrogen substitution in the menopause. Rate Control in Drug Therapy, L. F. Prescott, W. S. Nimmo. Churchill Livingstone, Edinburgh 1985; 294–303
   Google Scholar
• Shaw J. E., Chandrasekaran S. K. Transdermal therapeutic systems. Drug Absorption, L. F. Prescott, W. S. Nimmo. ADIS Press, New York 1981; 186–193
   Google Scholar
• Sloan K. B., Bodor N. Hydroxymethyl and acyloxymethyl pro-drugs of theophylline: enhanced delivery of polar drugs through skin. International Journal of Pharmaceutics 1982; 12: 299–313
   Web of Science ®Google Scholar
• Tauber U. Metabolism of drugs on and in the skin. Dermal and Transdermal Absorption, R. Brandau, B. H. Lippold. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1981; 133–151
   Google Scholar
• Vlasses P. H., Ribeiro L. G. T., Rotmensch H. H., Bondi J. V., Loper A. E., Hichens M., Dunlay M. C., Ferguson R. K. Initial evaluation of transdermal timolol: serum concentrations and β-blockade. Journal of Cardiovascular Pharmacology 1985; 7: 245–250
   PubMed Web of Science ®Google Scholar
• Weber M. A., Drayer J. I. M., Brewer D. D., Lipson J. L. Transdermal continuous antihypertensive therapy. Lancet 1984; 1: 9–11
   PubMed Web of Science ®Google Scholar
• Wester R. C., Noonan P. K., Smeach S., Kosobud L. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey. Estimate of percutaneous first-pass metabolism. Journal of Pharmaceutical Sciences 1983; 72: 745–748
   PubMed Web of Science ®Google Scholar
• Wolff M., Cordes G., Luckow V. In vitro and in vivo-release of nitroglycerin from a new transdermal therapeutic system. Pharmaceutical Research 1985; 2: 23–29
   PubMedGoogle Scholar
• Yu C. D., Fox J. L., Ho N. F. H., Higuchi W. I. Physical model evaluation of topical pro-drug delivery-simultaneous transport and bioconversion of vidarabine-5′-valerate. I: Physical model development. Journal of Pharmaceutical Sciences 1979; 68: 1341–1346
   PubMed Web of Science ®Google Scholar